Klotho has emerged as a promising candidate in the realm of cognitive enhancement. Originally discovered for its role in regulating aging and longevity, Klotho has garnered significant attention for its potential to enhance brain function and protect against neurodegenerative diseases.
Research indicates that higher levels of Klotho are associated with improved cognitive abilities, suggesting its influence on memory, learning, and overall mental acuity. This protein operates through various mechanisms, including the modulation of cellular pathways and reduction of oxidative stress, making it a focal point in the search for therapies aimed at preserving and enhancing cognitive health throughout the aging process.
Clinical studies on Klotho and neurodegenerative diseases have highlighted its significant neuroprotective e ects. Research indicates that higher levels of Klotho are associated with improved cognitive function and a reduced risk of developing conditions like Alzheimer's diseases and Parkinson's diseases. Several studies have demonstrated that Klotho enhances synaptic function, reduces inflammation, and mitigates oxidative stress in the brain, all of which are critical factors in the progression of neurodegenerative diseases. Furthermore, genetic studies have revealed that individuals with certain Klotho gene variants exhibit better cognitive performance and slower cognitive decline. While more research is needed to fully understand the therapeutic potential, these findings suggest that Klotho could be a promising target for developing treatments to prevent or slow the progression of neurodegenerative diseases.
Brain expression of klotho was first described with the initial discovery of the klotho gene. The prominent age-regulating e ects of klotho are attributed to regulation of ion homeostasis through klotho function in the kidney. However, recent advances identified brain functions and cell populations, including adult hippocampal neural progenitors, which require klotho. As well, both human correlational studies and mouse models of diseases show that klotho is protective against multiple neurological and psychological disorders. This review focuses on current knowledge as to how the klotho protein effects the brain.
Brain Function in Elderly Monkeys Improves with Klotho Injection
https://www.nature.com/articles/d41586-023-02214-3
In their paper, published in the journal Nature Aging, the team describe the experiments they conducted giving the rhesus form of klotho to aging monkeys and what they found by doing so.
In this new effort, the research team wanted to know if giving aging monkeys the protein would slow or restore cognitive function. They selected 18 rhesus macaques that were equivalent in age to humans that were aged 65 or older.
Each was tasked to make their way through a maze in order to find a hidden treat. They were then encouraged to repeat the maze to see how well they remembered the most direct path to the treat. Next, the researchers injected klotho into each of the monkeys—the amount raised their levels to what it was when they were infants. After four hours, the monkeys were tested again with di erent mazes. They were also tested several times over the following two weeks.
In looking at their results the team found that giving the monkeys klotho led to improvements in working memory. They also found that the monkeys saw more improvements when the maze paths were more di cult to remember, in some cases by as much as 20%.
The researchers also found that the e ects of giving the monkeys klotho lasted for at least two weeks. They suggest their findings indicate that giving the protein to the monkeys led to cognitive improvement. More work needs to be done to find out if it can be given on a regular basis without causing harm, and if it would continue to provide improvements over time. If so, the team expect testing to begin with humans.
A Breakthrough in Alzheimer's diseases The promising potential of klotho for brain health, cognitive decline, and as a therapeutic tool for Alzheimer's diseases | Dena Dubal, M.D., Ph.D.
"I have this dream that people might be able someday to benefit from klotho, this factor that naturally circulates in our body, that helps with longevity, that helps with other organ systems and enhances the brain." —Dena Dubal
Source: https://search.app/wwqcnPceqhCFpKK37
Klotho controls the brain-immune system interface in the choroid plexus
https://pubmed.ncbi.nlm.nih.gov/30413620/
A Boost of Klotho Protein Level Has Therapeutic Potential in Amyotrophic Lateral Sclerosis (ALS), Also Known as Lou Gehrig's diseases
https://www.prnewswire.com/news-releases/a-boost-of-klotho-protein-level-has-therapeutic-potential-in-amyotrophic-lateral-sclerosis-als-also-known-as-lou-gehrigs-diseases-300876328.html
Study on Klotho by Alzheimer's Drug Discovery Foundation
https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Klotho-UPDATE.pdf
The Alzheimer's Foundation has conducted and supported various studies exploring the role of Klotho in Alzheimer's diseases and other neurodegenerative conditions. These studies have focused on understanding how Klotho protein levels influence brain health and cognitive function, aiming to uncover potential therapeutic targets.
Key findings from these studies include:
The Alzheimer's Foundation continues to support research on Klotho to better understand its mechanisms and therapeutic potential. The ultimate goal is to develop effective treatments that leverage Klotho's protective properties to slow or prevent the onset and progression of Alzheimer's diseases.
The Neuroprotective Effect of Klotho is Mediated via Regulation of Members of the Redox System
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148892/
Neuroprotective Role of Klotho on Dementia
https://pubmed.ncbi.nlm.nih.gov/37425590/
Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations
https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2022.931331/full
Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs
https://www.liebertpub.com/doi/full/10.1089/biores.2020.0004
The potential neuroprotective e ects of Klotho in Parkinson's diseases (PD) are a topic of significant interest in neuroscientific research. As of October 2023, there are notable interest and preclinical studies investigating the potential of Klotho in treating Parkinson's diseases (PD), but information on ongoing clinical trials specifically targeting Klotho for PD might not be readily available or might be limited in scope. Factors to Consider:
1. Preclinical Evidence
- Several preclinical studies highlight Klotho’s neuroprotective effects against dopaminergic neuron degeneration, a hallmark of PD. These studies involve
animal models and cellular models where Klotho showed promise in reducing neuroinflammation, oxidative stress, and enhancing neuronal survival.
Animal models of Parkinson's diseases have shown that Klotho administration can reduce neuroinflammation, protect dopaminergic neurons, and improve
motor functions.
Many studies also focus on animal models to understand how Klotho supplementation or upregulation can mitigate the progression of PD symptoms. These studies look at neuroprotective effects, reduction in neuroinflammation, and overall improvement in motor and cognitive functions.
- Research involving neuronal cell cultures aims to elucidate the molecular mechanisms through which Klotho acts, such as its interaction with various signalling pathways implicated in PD. Cellular models demonstrated Klotho’s protective effects against mitochondrial dysfunction and oxidative damage, crucial factors in PD progression.
- Exploring gene therapy approaches to increase endogenous Klotho production.
- Investigating small molecules or drugs that can upregulate Klotho expression. Investigating synthetic Klotho or Klotho-mimetics that can cross the blood-brain barrier effectively and deliver therapeutic benefits.
- Multi-target strategies where Klotho is one aspect of a broader therapeutic regimen, indirectly benefiting PD patients.
Neuroinflammation Modulation: Some trials focus on reducing neuroinflammation, where Klotho's properties might be beneficial.
Neuroprotective Agents: Broader trials assessing neuroprotective agents, which could include assessing biomarkers like Klotho for efficacy.
Trials aiming at enhancing neuroprotection in a broader context might include Klotho as a biomarker or part of a multi-targeted therapeutic strategy.
Some trials focus on Klotho as a biomarker for neurodegenerative diseases, assessing levels in patients, including those with PD, to understand correlations with diseases severity and progression.
Trials assessing Klotho in the context of cognitive declines, such as Mild Cognitive Impairment (MCI) and Alzheimer's diseases, could inform PD approaches. These studies help determine safety and efficacy, potentially setting the stage for PD-specific trials.
Researchers are likely working towards bridging the gap from laboratory findings to human trials, emphasizing the need for innovative delivery solutions and validating Klotho's e ects in human neurodegeneration contexts.
Klotho has antioxidant properties that help to neutralize reactive oxygen species (ROS), which are highly reactive chemicals that can damage cellular components.
Relevance to PD: Dopaminergic neurons in the substantia nigra are particularly vulnerable to oxidative stress. By reducing ROS, Klotho may help protect these neurons from degenerative processes.
Klotho can modulate the immune response by decreasing the production of pro-inflammatory cytokines and increasing anti-inflammatory cytokines. It also inhibits the activation of NFκB, a key regulator of inflammation.
Relevance to PD: Chronic neuroinflammation is a hallmark of PD. By dampening inflammatory pathways, Klotho could mitigate inflammatory damage to neurons.
Klotho has been shown to enhance mitochondrial function and biogenesis, promoting better energy production and reducing mitochondrial oxidative damage.
Relevance to PD: Mitochondrial dysfunction is a well-known contributor to PD pathogenesis. Improving mitochondrial function can sustain neuronal health and viability.
Klotho can promote the autophagy-lysosome pathway, which is essential for the degradation and recycling of damaged cellular components.
Relevance to PD: Dysfunctional autophagy leads to the accumulation of damaged proteins and organelles, contributing to neurodegeneration. By enhancing autophagy, Klotho may help in clearing misfolded proteins like alpha-synuclein, which aggregate in PD.
Klotho has been reported to improve synaptic function and enhance synaptic plasticity. It can increase the expression of synaptic proteins and promote dendritic spine formation.
Relevance to PD: Synaptic loss is an early event in PD progression. Klotho's ability to support synaptic health could slow down this aspect of the diseases.
Klotho can interact with and enhance the activity of various growth factors, including insulin-like growth factor-1 (IGF-1). This interaction supports cellular survival pathways.
Relevance to PD: Growth factors play a crucial role in maintaining neuronal health and preventing apoptosis. By modulating these pathways, Klotho could contribute to the survival of dopaminergic neurons.
Klotho influences gene expression and can exert epigenetic modifications that support neuroprotective gene profiles.
Relevance to PD: These genetic and epigenetic changes can result in a cellular environment that is more resilient to the stresses associated with PD.
Numerous studies in mouse models of PD have demonstrated that increasing Klotho levels can protect against motor deficits, reduce neuronal loss, and improve overall neuronal health.
In vitro studies with human neurons derived from induced pluripotent stem cells (iPSCs) have shown promising protective effects of Klotho against PD-related cellular stressors.
Ongoing efforts to develop small molecules that can upregulate endogenous Klotho expression or mimic its effects.
Potential strategies to deliver Klotho gene using viral vectors, especially targeting the central nervous system to ensure appropriate therapeutic levels.
Klotho is known to influence several inflammatory markers. Here's an overview of some specific inflammatory markers affected by Klotho:
High levels of IL-6 are often found in the brains of PD patients.
Klotho can reduce the production of IL-6, thereby mitigating its pro-inflammatory effects.
TNF-α is another cytokine elevated in PD and contributes to neuroinflammation and neurodegeneration.
Klotho has been shown to lower TNF-α levels, helping to protect neuronal cells.
IL-1β levels are elevated in the substantia nigra of PD brains.
Klotho modulates the levels of IL-1β, reducing inflammation and oxidative stress.
NF-κB pathway is implicated in PD-associated neuroinflammation.
Klotho negatively regulates NF-κB signalling, resulting in reduced inflammatory responses.
COX-2 is involved in the inflammatory process within the CNS.
Klotho inhibits COX-2 expression, leading to decreased inflammation.
ROS contribute to oxidative stress and inflammation in PD.
Klotho enhances antioxidant defenses, thus reducing ROS-mediated inflammation.
1. Delivery Methods: Safely delivering Klotho across the blood-brain barrier and ensuring its stability and activity in the human brain.
2. Regulatory Approvals: Navigating the stringent regulatory pathways to approve gene therapies or biologics that involve Klotho.
3. Longitudinal Studies: Establishing the long-term efficacy and safety of Klotho-based treatments, which require extensive longitudinal studies.
KLOTHO: THE SECRET TO LONGEVITY, ANTI-AGING, AND TRANSFORMATIVE HEALTH.
© Copyright 2025 Swiss Institute Klotho Research. All rights reserved
